Goodbody Health putting quality and compliance first with extension of scope of ISO 17025

Goodbody Health Inc

Goodbody Health Inc (CSE:GDBY / AQSE:GDBY / FRA: 484 / OTC: SCNNF) has announced today its subsidiary Phytovista Laboratories has achieved another significant milestone with an extension to its ISO 17025 UKAS accreditation with a test to meet Government Chemist and the Advisory Council on the Misuse of Drugs (“ACMD”) Guidance, one of a very small number of laboratories accredited for this type of testing.

As identified in the 2021 Government Chemist CBD Food and Cosmetic Ring Trial report, and others, advanced testing methodology is desirable to give the required sensitivity and selectivity to reliably detect traces of residues of controlled cannabinoids in consumer CBD products.

PhytoVista laboratories is now ideally positioned to help CBD companies achieve compliance by providing data in accordance with the ACMD guidance on acceptable levels of controlled cannabinoids in consumer products.

The Government Chemist has been recognised for their contribution in advising government and contributing to the ACMD, enabling the UK to lead the way in creating a fully regulated Novel Food consumer CBD market, facilitating consumer choice and confidence.

Geremy Thomas, Goodbody Health Executive Chairman, said; “This is another example to show how we as a group not only lead the way in supplying the best quality products but also continue to support the whole CBD industry to put quality and compliance first.”

You might also enjoy reading  Goodbody Health announces Annual General and Special Meeting of Shareholders
Find more news, interviews, share price & company profile here for:
Goodbody Health

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit
Find more news, interviews, share price & company profile here for:
Goodbody Health

AIM All Share Index